Flunarizine
Solid powder
Chemical Compounds
Flunarizine is a calcium channel blocker that is used for the treatment of various neurological disorders such as migraine, vertigo, and epilepsy. It was first synthesized in the 1960s and has since been extensively studied for its therapeutic potential.
303.29 g/mol
303.29 g/mol
Formulation:
303.29 g/mol
Source:
Usage:
Flunarizine
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-268305
CAS Number: 52468-60-7
Molecular Formula: C15H14FN3O3
Molecular Weight: 303.29 g/mol
| CAS Number | 52468-60-7 |
|---|---|
| Product Name | Flunarizine |
| Molecular Formula | C15H14FN3O3 |
| Molecular Weight | 303.29 g/mol |
| Appearance | Solid powder |
| InChI | InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+ |
| InChI Key | OFBIFZUFASYYRE-UHFFFAOYSA-N |
| IUPAC Name | 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine |
| Canonical SMILES | CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C |
| Description | Flunarizine is a calcium channel blocker that is used for the treatment of various neurological disorders such as migraine, vertigo, and epilepsy. It was first synthesized in the 1960s and has since been extensively studied for its therapeutic potential. |
| Method of Synthesis or Extraction | Flunarizine can be synthesized using various methods such as the reaction of 1-(4-chlorobenzyl)-4-(3-phenylpropyl)piperazine with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone or by reacting 1-(4-chlorobenzyl)-4-(3-phenylpropyl)piperazine with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone followed by reduction with sodium borohydride. The efficiency and yield of each method vary, but the latter method is preferred due to its higher yield. Environmental and safety considerations are also important, and the use of hazardous chemicals and solvents should be minimized. |
| Chemical Structure and Biological Activity | Flunarizine has a chemical formula of C26H26ClF2N3O and a molecular weight of 475.95 g/mol. It is a white to off-white crystalline powder that is soluble in water and ethanol. Flunarizine acts as a calcium channel blocker and inhibits the influx of calcium ions into cells, which leads to the relaxation of smooth muscles and the reduction of neurotransmitter release. It has been shown to have a high affinity for the L-type calcium channels and is also a potent inhibitor of the histamine H1 receptor. Flunarizine has been found to be effective in the treatment of migraine, vertigo, and epilepsy. |
| Biological Effects | Flunarizine has been shown to have various biological effects on cell function and signal transduction. It has been found to inhibit the release of neurotransmitters such as dopamine, serotonin, and noradrenaline, which are involved in the pathogenesis of migraine and other neurological disorders. Flunarizine has also been shown to have potential therapeutic and toxic effects. It has been found to be effective in the treatment of migraine, vertigo, and epilepsy, but it can also cause adverse effects such as drowsiness, weight gain, and extrapyramidal symptoms. |
| Applications | Flunarizine has various applications in medical research, environmental research, and industrial research. In medical research, it has been used in drug development and clinical trials for the treatment of migraine, vertigo, and epilepsy. It has been found to be effective in reducing the frequency and severity of migraine attacks and improving the quality of life of patients. In environmental research, flunarizine has been studied for its effects on ecosystems and its role in pollution management. It has been found to have a low environmental impact and can be used as a sustainable alternative to other chemicals. In industrial research, flunarizine has been used in manufacturing processes to improve product quality and efficiency. Health and safety considerations are important, and the use of flunarizine should be regulated to minimize adverse effects. |
| Future Perspectives and Challenges | Despite its therapeutic potential, flunarizine has some limitations in its use and study. It can cause adverse effects such as drowsiness, weight gain, and extrapyramidal symptoms, which can limit its use in some patients. Possible solutions and improvements include the development of new formulations and the use of lower doses. Future trends and prospects in the application of flunarizine in scientific research include the development of new drugs that target specific calcium channels and the use of flunarizine in combination with other drugs for the treatment of neurological disorders. Conclusion: Flunarizine is a calcium channel blocker that has been extensively studied for its therapeutic potential in the treatment of various neurological disorders. It has a high affinity for the L-type calcium channels and is also a potent inhibitor of the histamine H1 receptor. Flunarizine has various applications in medical research, environmental research, and industrial research. Despite its therapeutic potential, flunarizine has some limitations in its use and study, and future research should focus on developing new drugs and improving the safety and efficacy of flunarizine. |
| Melting Point | 201-203 °C 202.0 °C 201-203°C |
| Other CAS Number | 78755-81-4 |
| Physical Description | Solid |
| Shelf Life | >2 years if stored properly |
| SMILES | C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F |
| Solubility | Soluble in DMSO, not in water |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Synonyms | Anexate Flumazenil Flumazepil Lanexat Ro 15 1788 Ro 15-1788 Ro 151788 Romazicon |
| Reference | 1: Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P. [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol. 2003 May 16-31;36(10):907-12. Review. Spanish. PubMed PMID: 12766861. 2: Bebin M, Bleck TP. New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs. 1994 Aug;48(2):153-71. Review. PubMed PMID: 7527321. 3: Leone M, Grazzi L, La Mantia L, Bussone G. Flunarizine in migraine: a minireview. Headache. 1991 Jun;31(6):388-91. Review. PubMed PMID: 1889980. 4: Pauwels PJ, Leysen JE, Janssen PA. Ca++ and Na+ channels involved in neuronal cell death. Protection by flunarizine. Life Sci. 1991;48(20):1881-93. Review. PubMed PMID: 1850815. 5: Schmidt R, Oestreich W. Flunarizine in the treatment of vestibular vertigo: experimental and clinical data. J Cardiovasc Pharmacol. 1991;18 Suppl 8:S27-30. Review. PubMed PMID: 1726733. 6: Rascol O, Clanet M, Montastruc JL. Calcium antagonists and the vestibular system: a critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol. 1989;3 Suppl:79s-87s. Review. PubMed PMID: 2693294. 7: Van Nueten JM, Janssens WJ. Cerebral antivasoconstrictive effects of flunarizine. Acta Otolaryngol Suppl. 1988;460:42-9. Review. PubMed PMID: 3074619. 8: McLean MJ. In vitro electrophysiological evidence predicting anticonvulsant efficacy of memantine and flunarizine. Pol J Pharmacol Pharm. 1987 Sep-Oct;39(5):513-25. Review. PubMed PMID: 3333611. 9: Caers LI, De Beukelaar F, Amery WK. Flunarizine, a calcium-entry blocker, in childhood migraine, epilepsy, and alternating hemiplegia. Clin Neuropharmacol. 1987 Apr;10(2):162-8. Review. PubMed PMID: 3332609. 10: Wouters L, Amery W, Towse G. Flunarizine in the treatment of vertigo. J Laryngol Otol. 1983 Aug;97(8):697-704. Review. PubMed PMID: 6350513. 11: Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache. 1983 Mar;23(2):70-4. Review. PubMed PMID: 6343298. 12: Teive HA, Troiano AR, Germiniani FM, Werneck LC. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004 Jun;10(4):243-5. Review. PubMed PMID: 15120099. 13: Galhardo I, Coutinho MO, De Albuquerque ES, Medeiros Lde O. [Parkinson disease induced by flunarizine: report of a case]. Arq Neuropsiquiatr. 1993 Dec;51(4):546-8. Review. Portuguese. PubMed PMID: 8147761. 14: Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. J Cardiovasc Pharmacol. 1991;18 Suppl 8:S21-6. Review. PubMed PMID: 1726732. 15: Isler H. Flunarizine in migraine attack. J Cardiovasc Pharmacol. 1991;18 Suppl 8:S15-6. Review. PubMed PMID: 1726730. 16: Lastra Martínez L, Herranz Fernández J, Arteaga Manjón-Cabez R. [Flunarizine and dihydroergotamine in the treatment of migraine in children]. An Esp Pediatr. 1990 Mar;32(3):213-8. Review. Spanish. Erratum in: An Esp Pediatr 1990 Jun;32(6):566. PubMed PMID: 2189328. 17: Todd PA, Benfield P. Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs. 1989 Oct;38(4):481-99. Review. PubMed PMID: 2684591. 18: Bakchine S, Lacomblez L, Soubrié C. [Extrapyramidal syndrome during treatment with flunarizine]. Rev Neurol (Paris). 1988;144(12):833-4. Review. French. PubMed PMID: 3070697. 19: Kurihara J, Kato H. [Agents to improve cerebrovascular circulation and cerebral metabolism--flunarizine]. Nihon Rinsho. 1985 Feb;43(2):402-5. Review. Japanese. PubMed PMID: 3889415. 20: Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984 Jan;27(1):6-44. Review. PubMed PMID: 6141044. |
| PubChem Compound | Flunarizine |
| Last Modified | May 30 2023 |